Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...